LSI is Officially Heading to Singapore — Register for LSI Asia '25 Today

December Emerging Medical Technologies Report

Published January 2012 | 59 Pages | 30 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in December 2012.

All companies include technology, market(s), key executive, and contact information.

Two- to three-page executive summaries are provided on most of the companies. Executive summaries typically include:

• Company Contact Information
• Company Overview (structure, size, year founded, etc.)
• Competitive Landscape
• Technological Advantage
• Stage of Development
• Target Markets
• Financial Summary and Sales Forecasts
• Financing & Partnering Needs
• IP Position & Status
• Management Team
• Exit Strategy
• More

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


•1-A ratcheting 2.7mm percutaneous access grasper and 2-An electrosurgical pencil which lights up the surgical site with 3 bright LEDs powered by two Li-ion batteries contained within the pencil
•1-Excellagen(R) is a topical gel for wound care management and 2-Generx(R) is a DNA-based angiogenic biologic intended for the treatment of coronary artery disease
•1-TRC105 is a Phase 2 monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis; it is expected to complement chemotherapy and treatment with VEGF inhibitors, including Avastin(R) or Lucentis(R). 2-TRC102 is a Phase 2 ready small molecule inhibitor of base excision repair that reverses resistance to antimetabolite and alkylating agent chemotherapies
•A biodegradable, biocompatible polymer scaffold specifically designed to support tissue in-growth and regeneration in the meniscus, with additional applications for the shoulder and hip
•A hand-held device with a touch-screen interface that identifies a patient's preferred language and then collects his/her information, medical history, symptoms, and complaints, which are then summarized into the caregiver's language and can be accessed on the device/through a facility's electronic health records (EHR) system
•A unique single surgery solution for articular cartilage repair using a patented cell isolation and cell combination technique, in a cost-effective and minimally instrumented therapy
•Aerosol drug delivery systems, aimed predominately at the critical care respiratory market
•Automated devices for Remote Ischemic Conditioning (RIC), a non-invasive protocol that simply enables powerful innate protection in cardiovascular and stroke applications
•Automated ultrasound CT scanner that provides high resolution (sub-millimeter) whole breast images with unique visual and growth information about the bulk properties of tissues and physical structures within the breast
•ClearECG: The first-ever diagnostic ECG to perform during MRI testing and interventional procedures enabling: 1) cardiac-related patient safety monitoring, 2) up to 50% improved workflow, and 3) expansion into multi-billion dollar markets
•Contact and non-contact devices to advance the standard-of-care for treating wounds and other hard/soft tissue injuries
•Drug-releasing polymer-coated bone grafts used during orthopedic surgeries
•Enhanced therapeutics for health maintenance, disease prevention, and the treatment of certain cancers, infectious diseases, and Central Nervous System (CNS) disorders
•Innovative flat panel x-ray sources for new types of irradiators (blood transfusion GVHD) and stationary CT imaging systems, including breast tomosynthesis and phase contrast imaging
•Medical devices and procedures for optimizing fat distribution and metabolism and for tissue aspiration and processing, with targeted applications for: the bariatric market; the liposuction and body sculpting market; and fat autograft and adipocyte-derived stem cell processing and reinjection markets
•Minimally invasive, non-surgical products for: acne scars, cellulite reduction, circumference reduction, facial contouring, fractional skin resurfacing, muscle lifting, skin rejuvenation, skin tightening, and wrinkle reduction
•Neuromodulation for treating blindness-causing diseases to which there are no cures and limited approved therapies, including: Retinitis Pigmentosa (RP), Macular Degeneration, and Stargardt's disease
•New designs for IV catheters to improve efficiency, increase patient comfort, and save providers money
•Next-generation aerosol delivery system for direct-access of high-dose lung disease drugs, including anti-infectives, biotherapeutics, and cytotoxics, as an alternative to intravenous administration
•Next-generation treatment for stress urinary incontinence (SUI): a single incision office-based treatment that vastly reduces complications while retaining the efficacy of the sling
•Non-invasive Raman spectroscopy based in vivo diagnostic research and application to wellness, medical, and narcotic products
•Novel and inexpensive sensor technology that measures breath profiles with applications in: respiratory rate monitoring, lung cancer screening, and asthma monitoring/management
•Novel biomaterials that can be used in a wide array of tissue reconstruction applications, including but not limited to: urology, dermatology, osteoarthritis, and podiatry
•Patented "non-linear" platform that allows large implants and instruments to be inserted into the body through a small incision, turning most conventional spine procedures into user-friendly minimally invasive spine surgery (MISS)
•Photodynamic therapy for psoriasis, cutaneous T cell lymphoma (CTCL), and other skin diseases
•Proprietary, clinically validated technology using near infrared light therapy for regenerative medicine
•Technology that enhances the efficacy of current standard-of-care pharmaceuticals used in major psychiatric disorders with a high unmet medical need
•The most affordable patient kiosk and sign-in system on the market to improve office efficiency and HIPAA compliance
•The VortexZDS(TM) indwelling urological catheter is designed to replace the Foley catheter and eliminate Urinary Tract Infections (UTIs); there is no retention balloon, thus, no to-and-fro movement across the meatus, where the biofilm forms
•The world's first electronic "AutoFocal" Intraocular Lens (IOL) that is designed to give patients a complete visual range, providing effective near, intermediate, and distance vision

Work with us

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.